Pramlintide has 17 known drug interactions based on U.S. FDA drug labeling data. 5 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Insulin Aspart Injection, Insulin Degludec, Insulin Glargine. Patients taking Pramlintide should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 17
- Major
- 5
- Moderate
- 12
Major (5)
- Pramlintide + Insulin Aspart Injection— May increase the risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
- Pramlintide + Insulin Degludec— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
- Pramlintide + Insulin Glargine— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
- Pramlintide + Insulin Glargine-Yfgn— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
- Pramlintide + Insulin Lispro— May increase the risk of hypoglycemia; dose adjustment and increased glucose monitoring required.
Moderate (12)
- Pramlintide + Glimepiride— May increase the glucose-lowering effect of glimepiride, increasing susceptibility to hypoglycemia.
- Pramlintide + Glipizide— May increase glucose-lowering effect of glipizide and susceptibility to hypoglycemia; monitor closely.
- Pramlintide + Insulin Aspart-Szjj— May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
- Pramlintide + Insulin Degludec And Liraglutide— May increase risk of hypoglycemia; dosage reductions and increased glucose monitoring may be required.
- Pramlintide + Insulin Detemir— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
- Pramlintide + Insulin Glargine And Lixisenatide— May increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.
- Pramlintide + Insulin Glargine-Aglr— May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.
- Pramlintide + Insulin Glulisine— May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
- Pramlintide + Insulin Human— May increase risk of hypoglycemia; dose adjustment and increased glucose monitoring may be required.
- Pramlintide + Insulin Icodec-Abae— May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.
- Pramlintide + Insulin Lispro-Aabc— May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.
- Pramlintide + Repaglinide— May increase risk of hypoglycemia. Repaglinide dose reductions and increased glucose monitoring may be required.